Laverock Therapeutics, established in 2021 to commercialise the gene editing induced gene silencing (GEiGS) platform for all human therapeutic applications, has expanded its seed...
Eisai and Biogen's humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI Intravenous Infusion” (200 mg, 500mg, lecanemab) has been approved in Japan as a...
The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim and Eli Lilly and Company's Jardiance (empagliflozin) 10 mg tablets to reduce the...